Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 14, Issue 3, 2000, Pages 243-248

  Koster, Andreas ^b   Hansen, Roland ^b   Kuppe, Herrmann ^b   Hetzer, Roland ^b   Crystal, George J ^b   Mertzlufft, Fritz ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

Blood loss; Cross reactivity to Orgaran; Ecarin clotting time; Renal dysfunction; Standard and complex cardiac surgery; Zero balanced ultrafiltration

Indexed keywords

ACETYLSALICYLIC ACID; DANAPAROID; ECARIN; HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DRUG CHOICE; DRUG CROSS REACTIVITY; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULTRAFILTRATION;

EID: 0034053689     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/cr.2000.5861     Document Type: Article

References (22)

1. Slaughter TF, Greenberg CS: Heparin-associated thrombocytopenia and thrombosis - implications for perioperative management. Anesthesiology 87:667-675, 1997
2. Shorten GD, Comunale ME: Heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 10:521-530, 1996
3. Vun CM, Evans S, Chong BH: Cross-reactivity study of low-molecular-weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 81:25-32, 1996
4. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfracuonated heparin. N Engl J Med 332:1330-1335, 1995
5. Walls JT, Curtis JJ, Silver D, Boley TM: Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 108:686-693, 1990
6. Bauer TL, Arepaly G, Konkele BA, et al: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246, 1997
7. Koster A, Sodian R, Kuppe H, et al: Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 89:777-780, 1998
8. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561, 1993
9. O-Yurvati AH, Laub GW, Southgate TJ, McGrath LB: Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 57:1656-1658, 1994
10. Kraenzler EJ, Starr NJ, Miller ML, Schiavone WA: Heparin-associated thrombocytopenia: Management of patients for open heart surgery - case reports describing the use of iloprost. Anesthesiology 69:964-967, 1988
11. Salmenperä MT, Levy JH: Pharmacologic manipulation of hemostasis - anticoagulation, in Lake CL, Moore RA (eds): Blood: Hemostasis, Transfusion and Alternatives in the Perioperative Period. New York, NY, Raven Press, 1995, pp 105-117
12. Pötzsch B, Hund S, Madlener K, et al: Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 77:920-925, 1997
13. Nowak G, Bucha E, Gook T, et al: Pharmacology of r-hirudin in renal impairment. Thromb Res 66:707-715, 1992
14. Riess FC, Pötzsch B, Bleese N, et al: Rekombinantes Hirudin als Antikoagulanz für den kardiopulmonalen Bypass in der Herzchirurgie: Klinische Erfahrungen. Z Herz-, Thorax-Gefässchirurgie 11:79-87, 1997
15. Greinacher A, Völpel H, Janssens U, et al: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 99:73-80, 1999
16. Journois D, Israel-Biet D, Pouard P, et al: High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 85:965-976, 1996
17. Nowak G, Bucha E, Brauns I, Czerwinski R: Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT IJ): The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 109:354-358, 1997
18. Vanholder R, Camez A, Veys N, et al: Pharmacokinetics of recombinant hirudin in hemodialized end-stage renal failure patients. Thromb Haemost 77:650-655, 1997
19. Hornberger J, Best J, Geppert J, McClellan M: Risks and costs of end-stage renal disease after heart transplantation. Transplantation 66:1763-1770, 1998
20. Amin DM, Mant TG, Walker SM, et al: Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. Thromb Haemost 77:127-132, 1997
21. Bove CM, Casey B, Marder VJ: DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 75:471-475, 1996
22. Nowak G, Bucha E: Prothrombin conversion-intermediate effectively neutralizes toxic levels of hirudin. Thromb Res 80:317-325, 1995